Effect of dual blockade of renin - Angiotensin system on TGFβ1 and left ventricular structure and function in hypertensive patients

Journal of Human Hypertension

Volumn 21, Issue 4, 2007, Pages 307-315

  Scaglione, R ^a   Argano, C ^a   Di Chiara, T ^a   Parrinello, G ^a   Colomba, D ^a   Avellone, G ^a   Donatelli, M ^a   Corrao, S ^a   Licata, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; POTASSIUM; PROCOLLAGEN; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE; ARTICLE; ASTHENIA; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GENDER; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PATIENT SELECTION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; COLLAGEN TYPE I; COLLAGEN TYPE III; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ITALY; LOSARTAN; MALE; MIDDLE AGED; PREVALENCE; RAMIPRIL; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 33947378232     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002161     Document Type: Article

References (38)

1. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al., the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC VII JAMA 2003; 289: 2560-2572.
2. Muiesan MI, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti Rosei E. Association of change in left ventricular mass with prognosis during long term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
3. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272.
4. Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001; 16: 328-335.
5. Diez J, Laviades C. Monitoring fibrillar collagen turn-over in hypertensive heart disease. Cardiovasc Res 1997; 35: 202-205.
6. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE et al. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: A LIFE substudy. J Hum Hypert 2005; 19: 301-307.
7. Dostal DE. Regulation of cardiac collagen: Angiotensin and cross talk with local growth factors. Hypertension 2001; 37: 841-844.
8. Border WA, Noble NA. Transforming Growth Factorβ1 in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.16.
9. Li JM, Brooks G. Differential protein expression and subcellular distribution of TGF beta 1, beta2 and beta3 in cardiomyocites during pressure overload induced hypertrophy. J Mol Cell Cardiol 1997; 29: 2213-2224.
10. Parrinello G, Licata A, Colomba D, Di Chiara T, Argano C, Bologna P et al. Left ventricular filling abnormlaities and obesity-associated hypertension: Relationship with overproduction of circulating transforming growth factor β1. J Hum Hypertens 2005; 19: 543-550.
11. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K et al. Transforming growth factor β1 function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overload rats. Circulation 2002; 106: 130-135.
12. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson Rj, for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.
13. White HD, Aylward PEG, Huang Z, Dalby A, Weaver WD, Barvik S et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Result from the Valsartan in acute myocardial infarction trial (VALIANT). Circulation 2005; 112: 3391-3399.
14. Klingbeil AD, Schneider MP, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115(1): 41-46.
15. Raasch W, Johren O, Schwartz S, Gieselberg A, Dominiak P. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. J Hypertens 2004; 22: 611-618.
16. Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Komehl P, Hocker B et al. Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 rat. Hypertension 2000; 36: 747-754.
17. Altman DG, Schultz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al., for the CONSORT group. The 134: 663-694.
18. Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by ciclosporine: Demonstration of a transforming growth factor β dependent mechanism of inhibition of cell growth. Transplantation 1994; 57: 577-582.
19. Diez J, Laviades C, Mayor G, Gil MJ, Monreal L. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-1456.
20. Risteli J, Niemi S, Trivedi P, Mawntausta O, Mowatt AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino terminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715-718.
21. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitis O et al. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
22. Licata G, Scaglione R, Corrao S, Ganguzza A, Mazzola G, Arnone S et al. Heredity and obesity associated hypertension. Impact of hormonal characteristics and left ventricular mass. J Hypertens 1995; 13: 611-618.
23. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Mishio M et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43: 686-691.
24. Lorm E, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
25. Strawn WB, Dean RH, Ferrario CM. Novel mechanism linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000; 1: 11-17.
26. Navalkar S, Parthasarathy S, Santanam M, Khan BV. Irebesartan, angiotensin type I receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444.
27. Pfeffer MA, Swedeberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart diseases: The CHARM overall programme. Lancet 2003; 362: 759-766.
28. Mckelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100: 1056-1064.
29. Yamamoto K, Masuyama T, Sakata Y, Nishikawa M, Mano T, Yoshida J et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76-82.
30. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
31. Weber KT. Extracellular matrix remodelling in heart failure: A role for de novo angiotensin generation. Circulation 1997; 96: 4065-4082.
32. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimono M, Zhan Y et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103: 148-154.
33. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 2003; 23: 776-782.
34. Schultz JEJ, Witt SA, Glascock B, Nieman ML, Reiser P, Nix SL et al. TGFβ1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787-796.
35. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure overload rats. Circulation 2002; 106: 130-135.
36. Peters H, Border WA, Noble NA. Targeting TGFβ1 overexpression in renal disease: Maximizing the antifibrotic action of angiotensin blockade. Kidney Int 1998; 54: 1570-1580.
37. Azizi M, Guyene TI, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29: 634-640.
38. Forclaz A, Maillard M, NussBerger J, Brunner HR, Burruer M. Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE-inhibitor? Hypertension 2003; 41: 31-36.